

Contents

| | |
|--|------|
| Section: Dedication and Introduction by Carl Erik Mogensen | v |
| Aperitif by Edwin Gale, UK | vii |
| Contributors | xiii |
| Section: Overview | |
| 1. Pharmacoepidemiology of Diabetes | 3 |
| <i>Jørgen Rungby and Andrew J. Krentz</i> | |
| 2. New Definitions of Diabetes: Consequences | 9 |
| <i>Knut Borch-Johnsen</i> | |
| Section: Pharmacotherapy of Diabetes | |
| 3. The Insulin Resistance Syndrome: Concept and Therapeutic Approaches | 19 |
| <i>Gerald M. Reaven</i> | |
| 4. Medical Emergencies – Diabetic Ketoacidosis and Hyperosmolar Hyperglycaemia | 31 |
| <i>Niels Møller and K. George M.M. Alberti</i> | |
| 5. Notes on the Use of Glucagon in Type 1 Diabetes | 39 |
| <i>Carl Erik Mogensen</i> | |
| 6. Insulin and New Insulin Analogues, Insulin Pumps and Inhaled Insulin in Type 1 Diabetes | 41 |
| <i>Kjeld Hermansen</i> | |
| 7. Insulin and New Insulin Analogues with Focus on Type 2 Diabetes | 53 |
| <i>Sten Madsbad</i> | |
| 8. The Place of Insulin Secretagogues in the Treatment of Type 2 Diabetes in the Twenty-First Century | 67 |
| <i>Harald Stingl and Guntram Schernthaner</i> | |

| | | |
|---|--|-----|
| 9. | Metformin – from Devil to Angel | 77 |
| | <i>Guntram Schernthaner and Gerit Holger Schernthaner</i> | |
| 10. | The Glitazones, Lessons so Far | 87 |
| | <i>Monika Shirodkar and Serge Jabbour</i> | |
| 11. | Antidiabetic Combination Therapy | 99 |
| | <i>Henning Beck-Nielsen and Jan Erik Henriksen</i> | |
| 12. | The Incretin Modulators – Incretin Mimetics (GLP-1 Receptor Agonists) and Incretin Enhancers (DPP-4 Inhibitors) | 111 |
| | <i>Michael A. Nauck, Wolfgang E. Schmidt, and Juris J. Meier</i> | |
| 13. | The Role of Alpha-Glucosidase Inhibitors (Acarbose) | 143 |
| | <i>Markolf Hanefeld and Frank Schaper</i> | |
| 14. | Multifactorial Intervention in Type 2 Diabetes | 153 |
| | <i>Oluf Pedersen</i> | |
| Section: Treating the Comorbid Patient | | |
| 15. | Obesity and Pharmacological Treatment | 167 |
| | <i>Bjørn Richelsen</i> | |
| 16. | Management of Diabetic Dyslipidaemia. | 173 |
| | <i>D. John Betteridge</i> | |
| 17. | Coronary Intervention and Ischemic Cardioprotection in Diabetic Patients. | 187 |
| | <i>Torsten Toftegaard Nielsen</i> | |
| Section: Diabetic Complications and Side-effects | | |
| 18. | ACE-I and ARB and Blood Pressure Lowering, Including Effect on Renal Disease. Treatment of Advanced Diabetic Renal Disease. | 201 |
| | <i>Per Løgstrup Poulsen and Johan V. Poulsen</i> | |
| 19. | Aspirin and Antiplatelet Drugs in the Prevention of Cardiovascular Complications of Diabetes | 211 |
| | <i>Alberto Zanchetti</i> | |
| 20. | Glycosylation Inhibitors, PKC Inhibitors and Related Interventions Against Complications. | 219 |
| | <i>Aino Soro-Paavonen and Mark Cooper</i> | |
| 21. | Diabetic Foot Ulcers | 229 |
| | <i>Andrew Boulton and Frank Bowling</i> | |
| 22. | Pharmacotherapy in Diabetic Neuropathy | 237 |
| | <i>Anders Dejgaard and Jannik Hilsted</i> | |

| | | |
|--|--|-----|
| 23. | Pregnancy – Pharmacological Problems. | 249 |
| | <i>Elisabeth R. Mathiesen and Peter Damm</i> | |
| 24. | Pharmacotherapy of Diabetic Retinopathy | 255 |
| | <i>Toke Bek</i> | |
| 25. | Pharmacotherapy in Diabetic Sexual Dysfunction | 261 |
| | <i>Niels Ejskjaer</i> | |
| 26. | A Bone Perspective | 267 |
| | <i>Lars Rejnmark</i> | |
| Section: Notes from Major Pharmaceutical Companies (all major companies asked to participate) | | |
| 27. | Achieving Guideline Control with New Pharmacotherapies: Albumin-Binding by Acylation of Insulin and GLP-1 | 273 |
| | <i>Mads Krogsgaard Thomsen</i> | |
| 28. | Pharmacotherapy of Diabetes. | 277 |
| | <i>Post Scriptum by the Editor</i> | |
| Index. | | 283 |

Pharmacotherapy of Diabetes: New Developments
Improving Life and Prognosis for Diabetic Patients

Mogensen, C.E. (Ed.)

2007, X, 289 p. 45 illus., Hardcover

ISBN: 978-0-387-69736-9